Skip to main content
2025 IDWeek Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
Live Streamed
On Demand
On Demand
View Session Discussion + Q&A

Oral Abstract Session
Session Type: Oral Abstract

119 - TB and Beyond: Innovations in Treatment, Resistance and Real-World Reach

Tuesday, October 21, 2025
10:30 AM - 11:45 AM US ET
Location: B207-B208

Live Streamed On Demand
CME Credits: Maximum of 0 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 0 hours of MOC Credit
CNE Credits: Maximum of 0 hours of ANCC Credit
ACPE Credits: ACPE 0 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 0 of PACE contact hours
CE Broker: Maximum of 0 CE broker credit hours
Disclosure(s):
Mariana Angelica Kundro, MD: No financial relationships to disclose.
Sheela Shenoi, MD MPH: Merck and Company, Inc.: My spouse worked for Merck 1997-2007 and retains stock in his retirement account. There is no conflict of interest, but included for full disclosure.

Presentations:

  • 10:30 AM - 10:42 AM US ET
    Comparative Efficacy of Rifamycin-containing Regimens in a Murine Model of Tuberculous Meningitis

    Presenting Author: Xueyi Chen, MD (she/her/hers) – Johns Hopkins University School of Medicine

    Co-Author: Carlos E. Ruiz-Gonzalez, MD – Johns Hopkins University School of Medicine

    Co-Author: Yuderleys Masias-Leon, M.D – Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.

    Co-Author: Medha Singh, PhD (she/her/hers) – Johns Hopkins University

    Co-Author: Oscar J. Nino-Meza, MD – Johns Hopkins University School of Medicine

    Co-Author: Dmitri Artemov, PhD – Johns Hopkins University School of Medicine

    Co-Author: Charles Peloquin, PharmD – University of Florida College of Pharmacy

    Co-Author: Sanjay K. Jain, MD – Johns Hopkins University School of Medicine

  • 10:42 AM - 10:54 AM US ET
    Efficacy, Safety, and Completion of Modified Short-Course Rifapentine and Isoniazid for Latent Tuberculosis Infection in High-Risk Patients with Rheumatic Disease: A Multicenter Randomized Controlled Trial

    Presenting Author: lifan zhang, MD – Peking Union Medical College Hospital,

    Co-Author: yujie he, n/a – The First Affiliated Hospital of Zhengzhou University

    Co-Author: wenwen wang, n/a – The Second Affiliated Hospital of Zhejiang University School of Medicine

    Co-Author: lijun wu, n/a – People’s Hospital of Xinjiang Uygur Autonomous Region

    Co-Author: xiaoxia zuo, n/a – Xiangya Hospital, Central South University

    Co-Author: sheng chen, n/a – Renji Hospital, School of Medicine, Shanghai Jiao Tong University

    Co-Author: yanping zhao, n/a – The First Affiliated Hospital of Harbin Medical University

    Co-Author: ping zhu, n/a – Xijing Hospital, Fourth Military Medical University

    Co-Author: hongbin li, n/a – The Affiliated Hospital of Inner Mongolia Medical University

    Co-Author: xiaoqing liu, n/a – Peking Union Medical College Hospital

  • 10:54 AM - 11:06 AM US ET
    Short-Course Tuberculosis Preventive Therapy in a High-Migration Setting: Experience from Suburban Cook County, Illinois

    Presenting Author: Samuel J. Starke, MD – Rush University

    Co-Author: Keziah Thomas, CRNP – Cook County Department of Public Health

    Co-Author: Ronald Lubelchek, MD – Cook County Department of Public Health

  • 11:06 AM - 11:18 AM US ET
    Microbiological Outcomes of Oral Omadacycline Treatment in Adults with Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Caused by Mycobacterium abscessus complex (MABc): Results from a Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Trial

    Presenting Author: Reeti Khare, PhD – National Jewish Health

    Co-Author: Diane M. Anastasiou, BS (she/her/hers) – Paratek Pharmaceuticals, Inc.

    Co-Author: Surya Chitra, PhD – Paratek Pharmaceuticals, Inc.

    Co-Author: Alisa W. Serio, PhD – Paratek Pharmaceuticals, Inc.

  • 11:18 AM - 11:30 AM US ET
    Impact of Anti-tuberculosis Drugs on Mycobacteriophage D29 Infectivity in Mycobacterium smegmatis Host Cells

    Presenting Author: Juliano H. Ito, BSc, Biomedicine (he/him/his) – Laboratory of Medical Bacteriology, Department of Clinical Analysis and Biomedicine, State University of Maringá

    Co-Author: Jean Meneguello, PhD – Laboratory of Medical Bacteriology, Department of Clinical Analysis and Biomedicine, State University of Maringá

    Co-Author: Regiane Scodro, PhD – Laboratory of Medical Bacteriology, Department of Clinical Analysis and Biomedicine,State University of Maringá

    Co-Author: Katiany Caleffi-Ferracioli, PhD – Laboratory of Medical Bacteriology, Department of Clinical Analysis and Biomedicine,State University of Maringá

    Co-Author: Rosilene Cardoso, PhD – Laboratory of Medical Bacteriology, Department of Clinical Analysis and Biomedicine, State University of Maringá

  • 11:30 AM - 11:43 AM US ET
    Evaluating the Clinical Impact of Molecular Drug Susceptibility Testing in Patients with Drug-Resistant Tuberculosis in Los Angeles County

    Presenting Author: Kyla Sherwood, MD MS – Palo Alto VA

    Co-Author: Shom Dasgupta-Tsinikas, MD – Los Angeles County Department of Public Health

    Co-Author: David L. Fuller, II, MD – Los Angeles County Department of Public Health